KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.

Lorcan McGarvey, Mandel Sher, Yury Grigorievich Shvarts, Susan Lu, Wen-Chi Wu, Ping Xu, Jonathan Schelfhout, Carmen La Rosa, Allison Martin Nguyen, Paul A Reyfman, Amna Sadaf Afzal

Lung 201(2) 111-118

PMID36879087
PMCIDPMC10115701
DOI10.1007/s00408-023-00606-w
发表日期2023-03-06
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

PURPOSE: We evaluated gefapixant, a P2X3 receptor antagonist, in participants with recent-onset (≤ 12 months) refractory chronic cough (RCC) or unexplained chronic cough (UCC). METHODS: Participants (≥ 18 years of age; ≥ 40 mm on a 100-mm cough severity visual analog scale [VAS] at screening and randomization) with chronic cough for < 12 months were enrolled in this phase 3b, double-blind, placebo-controlled, parallel group, multicenter study (NCT04193202). Participants were randomized 1:1 to gefapixant 45 mg BID or placebo for 12 weeks with a 2-week follow-up. The primary efficacy endpoint was change from baseline at Week 12 in Leicester Cough Questionnaire (LCQ) total score. Adverse events were monitored and evaluated. RESULTS: There were 415 participants randomized and treated (mean age 52.5 years; median [range] duration 7.5 [1-12] months): 209 received placebo and 206 received gefapixant 45 mg BID. A statistically significant treatment difference of 0.75 (95% CI: 0.06, 1.44; p = 0.034) for gefapixant vs. placebo was observed for change from baseline in LCQ total score at Week 12. The most common AE was dysgeusia (32% gefapixant vs. 3% placebo participants); serious AEs were rare (1.5% gefapixant vs. 1.9% placebo participants). CONCLUSION: Gefapixant 45 mg BID demonstrated significantly greater improvement in cough-specific health status from baseline compared to placebo, in participants with recent-onset chronic cough. The most common AEs were related to taste and serious AEs were rare.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。